NKTR AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
NKTR Current Performance
0.73%
Nektar therapeutics
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to NKTR
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
VTGN | Vistagen therapeutics, inc. | 3 | 3 | 2 | 2 | 1 | |
TNGX | Tango therapeutics inc | 2 | 4 | 3 | 2 | 1 | |
DTIL | Precision biosciences inc | 2 | 2 | 2 | 2 | 1 | |
PSTX | Poseida therapeutics inc | 2 | 4 | 3 | 3 | 1 | |
ANIP | Ani pharmaceuticals inc | 3 | 3 | 4 | 3 | 1 |
- VTGN Vistagen therapeutics, inc.Value 3Trend 3Swing Trading 2Whale Interest 2Dividend 1See more
NKTR Profile
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.